SB 493 - Currently, the prohibition on the prescription or administration of cross-sex hormones or puberty-blocking drugs for the purpose of a gender transition for persons under 18 years of age expires on August 28, 2027. This act removes that expiration date. This act is identical to SB 26 (2025), SB 249 (2025), SB 1185 (2024), SB 726 (2024), and SB 776 (2024), substantially similar to SB 75 (2025), and similar to provisions in HCS/HBs 1520, 1519, 2355, and 2357 (2024).
SARAH HASKINS